Who we are
GlycoCore Pharma srl is a start-up specialized in the development of biopolymers as new therapeutics for respiratory diseases. Our goal is to develop pharmaceuticals based on the active principle HYLACH® to employ in respiratory conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).
Our development strategy relies on molecular design approaches evaluating the intrinsic properties of the biopolymeric moiety and the receptor features of the target tissues. Specificity towards proteins that are highly expressed in pathological conditions may assure a target intervention in affected tissues.
The new biopolymer HYLACH®, a hyaluronic acid chain functionalized by lactose derivatives, couples the high biocompatibility of hyaluronic acid with the anti-inflammatory/fibrotic performances gained from the lactose derivative affinity for galectins, a class of molecules highly expressed in inflammatory and fibrotic conditions.
Experimental data confirmed the technical feasibility, and we are currently investigating HYLACH® performances in a preclinical stage. Preliminary data confirm HYLACH® capacity in downregulating galectins in inflamed tissues. Besides, HYLACH® interferes in the expression of citokines of the inflammatory environment such as TGF-β.